Date: Monday, November 9, 2020
Session Type: Poster Session D
Session Time: 9:00AM-11:00AM
Background/Purpose: Behçet’s disease (BD) is a multisystemic vasculitis. Different clinical phenotypes can be distinguished. Systemic corticosteroids are the most used drugs in BD. Conventional and biological immunosuppressants (IS) may also be used. Objectives: To evaluate the systemic treatment of BD according to clinical domains
Methods: Study of all consecutive 111 patients diagnosed with definitive or possible BD by expert rheumatologists in a well-defined population of Northern Spain, between 1980 and 2019. Most of them met the International Criteria for BD (ICBD) Study of all consecutive 111 patients diagnosed with definitive or possible BD by expert rheumatologists in a well-defined population of Northern Spain, between 1980 and 2019. Most of them met the International Criteria for BD (ICBD).
Results: We studied 111 patients (62 women/49 men), mean age at diagnosis 36.8±13.2 years. After a mean follow-up of 81.4±85 months, all patients required systemic treatment (TABLE 1-2). Biological therapy (n=28) was indicated by ocular manifestations (n=13; 46.4%) persistent, severe and refractory oral ulcers (n=10, 35.7%), neurological (n=2; 7.1%), musculoskeletal (n=2; 7.1%) or cutaneous involvement (1; 3.6%). Adalimumab and Infliximab were the biological therapy more frequently used.
Conclusion: Most patients with BD required oral corticosteroids and colchicine. Almost half required conventional IS. Up to a third required biologic therapy, especially by ocular involvement. Most patients had clinical improvement.
To cite this abstract in AMA style:Martinez-Lopez D, Sanchez-Bilbao L, Alvarez-Reguera C, Herrero Morant A, Gonzalez-Mazon I, Martín-Varillas J, Suarez-Amorin G, Setien-Preciados P, Mata-Arnaiz C, González-Gay M, Blanco R. Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/systemic-treatment-in-behcets-disease-according-to-clinical-phenotypes-study-of-111-patients/. Accessed October 5, 2022.
« Back to ACR Convergence 2020
ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-treatment-in-behcets-disease-according-to-clinical-phenotypes-study-of-111-patients/